Difference between revisions of "Part:BBa K5036006"

(Software Characterization)
(Dry lab Characterization)
 
(10 intermediate revisions by 2 users not shown)
Line 7: Line 7:
  
 
==Usage==
 
==Usage==
This is the extracellular domain of the second chain dCas9-synRTK receptor which respond specifically to vascular endothelial growth factor (VEGF) which is a specific substance for wounds so when activated it transduce the signal causing dimerization of the two receptor chains and thus help in the control of transcription and prevent auto activation.
+
This is the extracellular domain of the second chain dCas9(N)-synVEGFR2 receptor which respond specifically to vascular endothelial growth factor (VEGF) which is a specific substance for wounds so when activated it transduce the signal causing dimerization of the two receptor chains and thus help in the control of transcription and prevent auto activation.
  
 
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
Line 24: Line 24:
 
.  </span></p></div></html>
 
.  </span></p></div></html>
  
==Literature Characterization==
+
==Dry lab Characterization==
In this study, a group of 34 angiosarcomas were examined  using immunohistochemistry technique which allowed  to assess the levels of proteins involved in blood vessel growth, including vascular endothelial growth factors (VEGF-A and VEGF-C) and their corresponding receptors (VEGFR-1, VEGFR-2, and VEGFR-3).
+
We started performing homology modelling to predict our external domains’ three-dimensional structure through Swiss model online tool that uses template homology modelling method to predict the 3D structure.
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
+
width:75%;
+
height:auto;
+
position: relative;
+
top: 50%;
+
left: 35%;
+
transform: translate( -50%);
+
padding-bottom:25px;
+
padding-top:25px;
+
"src="https://static.igem.wiki/teams/5036/parts/kx-td3ckcza-asqqnz8t0z5iqyu9aglwbs7xflvheuhyrju9tg8rxqbdpw3wj9juw98op8korgmnrzto3zhbumcazvcowhloic0nixtl74ae2bel7ovpovbiso2t-gwu-1lz3dgxfjh-jodyroyq8qhklxz8bib4h2yeqs-p213.png
+
">
+
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+
lang=EN style='font-size:11.0pt;line-height:115%'>VEGF-A was expressed by 32/34 (94%), VEGF-C by 4/34 (12%), VEGFR-1 by 32/34 (94%), VEGFR-2 by 22/34 (65%), and VEGFR-3 by 27/34 (79%)
+
.  </span></p></div></html>
+
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
+
width:100%;
+
height:auto;
+
position: relative;
+
top: 50%;
+
left: 45%;
+
transform: translate( -50%);
+
padding-bottom:25px;
+
padding-top:25px;
+
"src="https://static.igem.wiki/teams/5036/parts/kx-td33bmoqbkmjuswiqfdsin7d6mkh5xb-k9q-hou1u1z1szpd3uw6xmheaptj1qz8w-jmd6naahc6i5anjl79lss96r5eyslxukq-k0ut7obj2vbqheh3rifyxzpxpvyooxgiudzunz757dqejply0-qxfccbz-n9rbm1qamvh.png
+
">
+
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
+
lang=EN style='font-size:11.0pt;line-height:115%'>The figure shows immunohistochemical staining of proteins associated with blood vessel growth in angiosarcoma scalp tissue. Panel A reveals strong positivity for VEGF-A in tumor cells. Panels B and C demonstrate consistent positivity for VEGFR-1 and VEGFR-3, respectively, in the lining of tumor cells. Panel D shows VEGF-C expression within the angiosarcoma, surrounded by lighter areas containing lymphocyte immune cells.
+
  </span></p></div></html>
+
 
+
==Software Characterization==
+
To choose the best external domain among the VEGFR2, we started performing homology modelling to predict our external domains’ three-dimensional structure through Swiss model online tool that uses template homology modelling method to predict the 3D structure.
+
  
 
<html>
 
<html>
Line 84: Line 53:
  
 
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
lang=EN style='padding-bottom:40px;font-size:11.0pt;line-height:115%'>this figure The Ramachandran plot shows that 93.36% of the VEGFR2 amino acid residues lie in a favorable region, indicating a stable protein structure. On the other hand, 0.89% of amino acid residues are considered as outliers.  
+
lang=EN style='padding-bottom:40px;font-size:11.0pt;line-height:115%'> The Ramachandran plot shows that 93.36% of the VEGFR2 amino acid residues lie in a favorable region, indicating a stable protein structure. On the other hand, 0.89% of amino acid residues are considered as outliers.  
 
.  </span></p></div></html>
 
.  </span></p></div></html>
  
Line 105: Line 74:
 
.  </span></p></div></html>
 
.  </span></p></div></html>
  
Then, In order to measure the binding stability between VEGFR1-2 and their ligand VEGFA, which is the main function of the external domain, we performed molecular docking using alpha fold 3 server.  
+
Then, we measured the binding stability between VEGFR2 and its ligand VEGFA, which is the main function of the external domain, we performed molecular docking using alpha fold 3 server.  
  
 
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
Line 121: Line 90:
 
lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>The alignment plot shows positive alignment between the 3D structure’s amino acids and the experimental structures in the diagonal line indicating good protein structure. Additionally, they scored binding stability (ΔG) of -9.2 kcal mol-1.
 
lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>The alignment plot shows positive alignment between the 3D structure’s amino acids and the experimental structures in the diagonal line indicating good protein structure. Additionally, they scored binding stability (ΔG) of -9.2 kcal mol-1.
  
 +
  </span></p></div></html>
 +
Then, we performed molecular dynamics for VEGFR2-VEGFA complex to measure its stability in normal physiological conditions
 +
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 +
width:75%;
 +
height:auto;
 +
position: relative;
 +
top: 50%;
 +
left: 35%;
 +
transform: translate( -50%);
 +
padding-bottom:25px;
 +
padding-top:25px;
 +
"src="https://static.igem.wiki/teams/5036/part-software/md-vegfr2.gif
 +
">
 +
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 +
lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>Being simulated in normal physiological conditions by amber notebook, VEGFR-2 shows an initial rise in RMSD from 2Å to 5Å which indicates changes in surrounding environment and conditions. After that, a state of narrow fluctuation and deviation, respectively, indicating a stable protein with deviation not more than 2 Å.
 
   </span></p></div></html>
 
   </span></p></div></html>
  
Then, we performed directed evolution using EV couplings to detect the highest and the lowest epistatic fitness of the VEGFR1 to be used in our project to choose the best mutant variant of the VEGFR1
+
Then, we performed directed evolution using EV couplings to detect the highest epistatic fitness and independent score of the VEGFR2 to be used in our project to choose the best mutant variant of the VEGFR2
  
  
Line 140: Line 124:
 
lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>This heatmap shows VEGFR-2 mutational landscape which is generated by EVcouplings software. It shows that the mutant variant associated with the highest epistatic fitness was (Y 418 N), meanwhile the highest independent score was also related to the (Y 418 N).
 
lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>This heatmap shows VEGFR-2 mutational landscape which is generated by EVcouplings software. It shows that the mutant variant associated with the highest epistatic fitness was (Y 418 N), meanwhile the highest independent score was also related to the (Y 418 N).
 
   </span></p></div></html>
 
   </span></p></div></html>
 +
 +
==Characterization by Mathematical Modeling==
 +
The model provides the interaction kinetics of VEGFR2 external domain upon binding of VEGF to it , the result shows satisfactory binding state and stability based on parametric values from literature.
 +
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 +
width:75%;
 +
height:auto;
 +
position: relative;
 +
top: 50%;
 +
left: 35%;
 +
transform: translate( -50%);
 +
padding-bottom:25px;
 +
padding-top:25px;
 +
"src="https://static.igem.wiki/teams/5036/parts-modeling/unnamed-1.png
 +
">
 +
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 +
lang=EN style='padding-bottom:30px;font-size:11.0pt;line-height:115%'>
 +
Graph (1). illustrates the decreasing of VEGFR2 (Red line) upon binding of VEGF (A) to form VEGF-VEGFR2 complex (R2A) (Yellow line) which increases till its binding to VEGFR1 (R1), so (R1) also decreases after will ( Black line). To finally form a binding state of fitted ligand receptor complex (R2AR1) (Blue line).
 +
.  </span></p></div></html>
 +
 +
==Literature Characterization==
 +
In this study, a group of 34 angiosarcomas were examined  using immunohistochemistry technique which allowed  to assess the levels of proteins involved in blood vessel growth, including vascular endothelial growth factors (VEGF-A and VEGF-C) and their corresponding receptors (VEGFR-1, VEGFR-2, and VEGFR-3).
 +
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 +
width:75%;
 +
height:auto;
 +
position: relative;
 +
top: 50%;
 +
left: 35%;
 +
transform: translate( -50%);
 +
padding-bottom:25px;
 +
padding-top:25px;
 +
"src="https://static.igem.wiki/teams/5036/parts/kx-td3ckcza-asqqnz8t0z5iqyu9aglwbs7xflvheuhyrju9tg8rxqbdpw3wj9juw98op8korgmnrzto3zhbumcazvcowhloic0nixtl74ae2bel7ovpovbiso2t-gwu-1lz3dgxfjh-jodyroyq8qhklxz8bib4h2yeqs-p213.png
 +
">
 +
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 +
lang=EN style='font-size:11.0pt;line-height:115%'>VEGF-A was expressed by 32/34 (94%), VEGF-C by 4/34 (12%), VEGFR-1 by 32/34 (94%), VEGFR-2 by 22/34 (65%), and VEGFR-3 by 27/34 (79%)
 +
.  </span></p></div></html>
 +
<html><div align="center"style="border:solid #17252A; width:100%;float:center;"><img style="                              max-width:850px;
 +
width:100%;
 +
height:auto;
 +
position: relative;
 +
top: 50%;
 +
left: 45%;
 +
transform: translate( -50%);
 +
padding-bottom:25px;
 +
padding-top:25px;
 +
"src="https://static.igem.wiki/teams/5036/parts/kx-td33bmoqbkmjuswiqfdsin7d6mkh5xb-k9q-hou1u1z1szpd3uw6xmheaptj1qz8w-jmd6naahc6i5anjl79lss96r5eyslxukq-k0ut7obj2vbqheh3rifyxzpxpvyooxgiudzunz757dqejply0-qxfccbz-n9rbm1qamvh.png
 +
">
 +
<p class=MsoNormal align=center style='text-align:left;border:none;width:98% ;justify-content:center;'><span
 +
lang=EN style='font-size:11.0pt;line-height:115%'>The figure shows immunohistochemical staining of proteins associated with blood vessel growth in angiosarcoma scalp tissue. Panel A reveals strong positivity for VEGF-A in tumor cells. Panels B and C demonstrate consistent positivity for VEGFR-1 and VEGFR-3, respectively, in the lining of tumor cells. Panel D shows VEGF-C expression within the angiosarcoma, surrounded by lighter areas containing lymphocyte immune cells.
 +
  </span></p></div></html>
 +
  
 
==Reference==
 
==Reference==
 
Itakura, E., Yamamoto, H., Oda, Y., & Tsuneyoshi, M. (2008). Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. Journal of surgical oncology, 97(1), 74-81.‏
 
Itakura, E., Yamamoto, H., Oda, Y., & Tsuneyoshi, M. (2008). Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. Journal of surgical oncology, 97(1), 74-81.‏
  
 
+
White C, Rottschäfer V, Bridge LJ. Insights into the dynamics of ligand-induced dimerisation via mathematical modelling and analysis. J Theor Biol. 2022 Apr 7;538:110996. doi: 10.1016/j.jtbi.2021.110996. Epub 2022 Jan 24. PMID: 35085533.
  
  

Latest revision as of 17:15, 30 September 2024


Vascular Endothelial Growth Factor Receptor 2 (VEGF-R2)

Part Description

It is vascular endothelial growth factor receptor which contain 3 members contain similar structures and their external parts are made up entirely of repeating segments that resemble parts of antibodies (immunoglobulin homology repeats) and they have a critical role in the formation of blood vessels and lymphatic vessels.


Usage

This is the extracellular domain of the second chain dCas9(N)-synVEGFR2 receptor which respond specifically to vascular endothelial growth factor (VEGF) which is a specific substance for wounds so when activated it transduce the signal causing dimerization of the two receptor chains and thus help in the control of transcription and prevent auto activation.

this figure illustrates the structure of the extracellular domain of our receptor's second chain .

Dry lab Characterization

We started performing homology modelling to predict our external domains’ three-dimensional structure through Swiss model online tool that uses template homology modelling method to predict the 3D structure.

(a)Ramachandran plot

(b)VEGFR2 3d structures

The Ramachandran plot shows that 93.36% of the VEGFR2 amino acid residues lie in a favorable region, indicating a stable protein structure. On the other hand, 0.89% of amino acid residues are considered as outliers. .

We also utilized Alpha fold3 server that uses de-novo homology modelling method to predict the 3D structure and to align this structure with the similar experimented structures.


The alignment plot of VEGFR2 shows high intensity along the diagonal line indicating high similarity between the 3D structure and the experimental structures. .

Then, we measured the binding stability between VEGFR2 and its ligand VEGFA, which is the main function of the external domain, we performed molecular docking using alpha fold 3 server.

The alignment plot shows positive alignment between the 3D structure’s amino acids and the experimental structures in the diagonal line indicating good protein structure. Additionally, they scored binding stability (ΔG) of -9.2 kcal mol-1.

Then, we performed molecular dynamics for VEGFR2-VEGFA complex to measure its stability in normal physiological conditions

Being simulated in normal physiological conditions by amber notebook, VEGFR-2 shows an initial rise in RMSD from 2Å to 5Å which indicates changes in surrounding environment and conditions. After that, a state of narrow fluctuation and deviation, respectively, indicating a stable protein with deviation not more than 2 Å.

Then, we performed directed evolution using EV couplings to detect the highest epistatic fitness and independent score of the VEGFR2 to be used in our project to choose the best mutant variant of the VEGFR2


This heatmap shows VEGFR-2 mutational landscape which is generated by EVcouplings software. It shows that the mutant variant associated with the highest epistatic fitness was (Y 418 N), meanwhile the highest independent score was also related to the (Y 418 N).

Characterization by Mathematical Modeling

The model provides the interaction kinetics of VEGFR2 external domain upon binding of VEGF to it , the result shows satisfactory binding state and stability based on parametric values from literature.

Graph (1). illustrates the decreasing of VEGFR2 (Red line) upon binding of VEGF (A) to form VEGF-VEGFR2 complex (R2A) (Yellow line) which increases till its binding to VEGFR1 (R1), so (R1) also decreases after will ( Black line). To finally form a binding state of fitted ligand receptor complex (R2AR1) (Blue line). .

Literature Characterization

In this study, a group of 34 angiosarcomas were examined using immunohistochemistry technique which allowed to assess the levels of proteins involved in blood vessel growth, including vascular endothelial growth factors (VEGF-A and VEGF-C) and their corresponding receptors (VEGFR-1, VEGFR-2, and VEGFR-3).

VEGF-A was expressed by 32/34 (94%), VEGF-C by 4/34 (12%), VEGFR-1 by 32/34 (94%), VEGFR-2 by 22/34 (65%), and VEGFR-3 by 27/34 (79%) .

The figure shows immunohistochemical staining of proteins associated with blood vessel growth in angiosarcoma scalp tissue. Panel A reveals strong positivity for VEGF-A in tumor cells. Panels B and C demonstrate consistent positivity for VEGFR-1 and VEGFR-3, respectively, in the lining of tumor cells. Panel D shows VEGF-C expression within the angiosarcoma, surrounded by lighter areas containing lymphocyte immune cells.


Reference

Itakura, E., Yamamoto, H., Oda, Y., & Tsuneyoshi, M. (2008). Detection and characterization of vascular endothelial growth factors and their receptors in a series of angiosarcomas. Journal of surgical oncology, 97(1), 74-81.‏

White C, Rottschäfer V, Bridge LJ. Insights into the dynamics of ligand-induced dimerisation via mathematical modelling and analysis. J Theor Biol. 2022 Apr 7;538:110996. doi: 10.1016/j.jtbi.2021.110996. Epub 2022 Jan 24. PMID: 35085533.


Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    INCOMPATIBLE WITH RFC[21]
    Illegal BglII site found at 364
    Illegal BglII site found at 1723
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    INCOMPATIBLE WITH RFC[1000]
    Illegal BsaI site found at 1236
    Illegal BsaI.rc site found at 46
    Illegal BsaI.rc site found at 824
    Illegal BsaI.rc site found at 2113